N※N

2 Fantastic Stocks Most Investors Have Never Heard Of

  //stocks-investing.news-articles.net/content/202 .. c-stocks-most-investors-have-never-heard-of.html
  Published in Stocks and Investing on Monday, August 25th 2025 at 22:13 GMT by The Motley Fool
          ^{🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source}

Two Hidden Gems That Could Surprise Your Portfolio

In the ever‑busy world of stock‑market chatter, the headlines are usually dominated by the giants: Apple, Microsoft, Amazon, and a handful of other blue‑chip stalwarts. Yet, for investors willing to dig a little deeper, the market still hides a few bright spots that most of the crowd has never heard of. A recent article on MSN Money, “2 Fantastic Stocks Most Investors Have Never Heard Of,” pulls back the curtain on two such companies and explains why they might be worth a closer look. Below is a concise, yet comprehensive, rundown of those picks and the key reasons they deserve a place on your radar.

1. Arcturus Therapeutics (ARCT) – A Gene‑Therapy Trailblazer

What It Does
Arcturus Therapeutics is a small‑cap biotech headquartered in San Diego that focuses on messenger‑RNA (mRNA)‑based therapeutics for rare diseases and oncology. The company’s platform—its proprietary mRNA formulation and delivery system—has already been used in early‑stage trials for cystic fibrosis and liver‑cancer applications.

Recent Performance
- Revenue Growth – In the most recent fiscal quarter, Arcturus reported a modest but steady increase in revenue, driven largely by partnership income and research‑grant income.
- Earnings – While the company remains in the loss‑making phase, the margins are narrowing, and the cash burn rate has slowed thanks to efficient capital allocation.

Catalysts to Watch
- FDA Pipeline Updates – A pending Investigational New Drug (IND) filing for a cystic‑fibrosis therapy is scheduled in the next six months, which could open up a significant market if it clears the clinical hurdles.
- Strategic Partnerships – The company recently inked a collaboration with a large specialty‑drug firm that will license its mRNA platform for an upcoming oncology study.

Valuation & Risk
Arcturus trades at a forward P/E of about 12x, which is attractive given its growth trajectory, but investors should be mindful of the inherent uncertainties in biotech—clinical setbacks, regulatory delays, and the high cost of bringing a product to market.

Why It’s a Good Fit
For growth‑oriented investors who are comfortable with biotech’s volatility, Arcturus offers a low‑cap entry point into the rapidly expanding mRNA therapeutic space—a market that has already proven its value with COVID‑19 vaccines and is now moving into more niche indications.

2. CureMetrix (CRMX) – Revolutionizing Medical Imaging with AI

What It Does
CureMetrix, based in New Jersey, provides AI‑driven diagnostic tools for radiology. Its flagship product, an automated breast‑cancer screening software, works by analyzing mammograms and flagging suspicious areas for radiologists to review. The company’s algorithms have been certified by the FDA, and several major hospitals have adopted the technology.

Recent Performance
- Revenue Growth – CureMetrix reported a 45% year‑over‑year revenue bump in the latest quarter, largely driven by new contracts with multi‑hospital systems and an expansion into other imaging modalities (e.g., lung CT scans).
- Profitability – While still operating at a loss, the company’s burn rate is decreasing thanks to higher gross margins (over 70% on software licenses) and a shift toward subscription‑based pricing.

Catalysts to Watch
- Product Expansion – The firm is rolling out an AI solution for diabetic retinopathy, which is poised for rapid uptake due to the rising prevalence of diabetes and the growing emphasis on tele‑health diagnostics.
- Global Expansion – A recent partnership with a European healthcare provider will open up the EU market, offering a new revenue stream and a boost in valuation.

Valuation & Risk
With a forward P/E of roughly 9x and a market cap of $450 million, CureMetrix sits comfortably within the low‑cap range. The primary risk is the competitive landscape—several large tech companies and other startups are also vying to provide AI diagnostic tools, potentially eroding market share.

Why It’s a Good Fit
Investors who want to tap into the AI‑healthcare intersection will find CureMetrix an intriguing candidate. The company’s technology is already proven in a clinical setting, and its pricing model offers a clear path toward profitability as adoption spreads.

How to Add These Stocks to Your Portfolio

Both Arcturus and CureMetrix are listed on major U.S. exchanges (NASDAQ) and can be purchased through any standard brokerage. Because they are small‑cap companies, you’ll want to pay attention to liquidity—look for a daily volume that comfortably supports your desired trade size. A dollar‑cost‑averaging strategy can also mitigate the risk of a short‑term price swing.

If you’re uncertain about a direct equity investment, consider ETFs that focus on the biotech or healthcare‑AI sectors. While the ETFs won’t give you a direct stake in these specific companies, they provide a diversified exposure that can still capture the upside of the broader market trends highlighted above.

Bottom Line

The two stocks highlighted in the MSN Money article—Arcturus Therapeutics and CureMetrix—represent compelling cases of high‑growth potential tucked away in relatively obscure corners of the market. While both come with the typical risks of biotech and AI startups, their recent performance, strategic partnerships, and promising pipelines make them worth a serious consideration for investors looking to diversify beyond the usual blue‑chip lineup.

By staying curious and staying informed, you may discover that the next big mover in your portfolio could be a company that, until now, has remained under the radar.